Balanced news tone
News Sentiment
688428 sentiment intelligence
InnoCare Pharma Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
11 relevant articles
Price is moving more forcefully than the current news tone suggests.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-10.9% over one week, +11.1% over four weeks, trend active, and materially above fair value.
InnoCare Pharma
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
75/100 classification
One-week reaction
-10.9%
Price reacting lower
Trend fit
Trend active
11.1% over four weeks
Fair value
55.8%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
8
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
The Pharma Letter
Direct company coverage
InnoCare Pharma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jul 2026 19:38
- Source
- The Pharma Letter
simplywall.st
Direct company coverage
InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 10:21
- Source
- simplywall.st
simplywall.st
Direct company coverage
Is InnoCare Pharma (SEHK:9969) Undervalued On Its Breakthrough Lupus Trial Results?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Jul 2026 22:20
- Source
- simplywall.st
Sahm
Direct company coverage
InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Sahm
China Daily
Direct company coverage
InnoCare Pharma posts 134% revenue surge in 2025, recording annual profit for first time
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 02 Feb 2026 08:00
- Source
- China Daily
Fierce Pharma
Direct company coverage
Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCare
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 08 Oct 2025 07:00
- Source
- Fierce Pharma
Reuters
Direct company coverage
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 08 Oct 2025 07:00
- Source
- Reuters
BioSpace
Direct company coverage
Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Oct 2025 07:00
- Source
- BioSpace
The Pharma Letter
Direct company coverage
Zenas inks license agreement with InnoCare for 3 autoimmune programs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Oct 2025 07:00
- Source
- The Pharma Letter
Fierce Biotech
Direct company coverage
InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 21 Jan 2025 08:00
- Source
- Fierce Biotech
TradingView
Direct company coverage
Technical Analysis of InnoCare Pharma Ltd. Class A (SSE:688428)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Mar 2023 11:22
- Source
- TradingView